Floatz logo

L-Leucine

Brain Diseases

Washington University School of MedicineDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

23 Active assets in the Brain Diseases cohort.

Asset / SponsorPhaseRating
Galantamine Hydrobromide
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3B
Live Combined Bifidobacterium
Beijing Friendship Hospital
Phase 4B
Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules
Beijing Friendship Hospital
Phase 4B
Fremanezumab
Hospital Clínico Universitario de Valladolid
Phase 4B
Donanemab
Eli Lilly and Company
Phase 3B

View all 43 →

Same molecule, other indications

L-Leucine is also rated in:

major depressive disorderDormant
CCC
Indicative ·
53 / 100
View asset →
central nervous system disorderDormant
D
Indicative ·
30 / 100
View asset →
Alzheimer diseaseDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →